Q2053Temporary Codes
Brexucabtagene autoleucel, up to 200 million autologous anti-cd19 car positive
Short description: Brexucabtagene car pos t
- Effective date
- April 1, 2021
- Termination date
- —
Related codes (Q-series)
Q0035CardiokymographyQ0081Infusion ther other than cheQ0083Chemo by other than infusionQ0084Chemotherapy by infusionQ0085Chemo by both infusion and oQ0091Obtaining screen pap smearQ0092Set up port xray equipmentQ0111Wet mounts/ w preparationsQ0112Potassium hydroxide prepsQ0113Pinworm examinationsQ0114Fern testQ0115Post-coital mucous exam
Frequently asked questions
What is HCPCS code Q2053?
Q2053 is a HCPCS Level II code for Brexucabtagene autoleucel, up to 200 million autologous anti-cd19 car positive.
What category is HCPCS code Q2053 in?
Q2053 falls under the Temporary Codes category of HCPCS Level II.
When did HCPCS code Q2053 become effective?
Q2053 has been effective since April 1, 2021, per CMS's quarterly HCPCS update.
HCPCS Level II data from CMS (public domain). HCPCS Level I (CPT) codes are not included — CPT is copyrighted by the American Medical Association. Always verify codes with authoritative sources before making coding or billing decisions.